액티니움 파마슈티컬스(ATNM)는 NYSE MKT에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.20 (+0.84%), 시가총액 $0.04B, 52주 최저~최고 $0.98 ~ $1.94.
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent
액티니움 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
액티니움 파마슈티컬스의 현재 주가는 $1.20 (+0.84%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
액티니움 파마슈티컬스의 시가총액은 약 $0.04B입니다.
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company